Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 4783-4792

  Matter, Hans ^a   Kumar, H S Arun ^h   Fedorov, Roman ^b,g   Frey, Armin ^c   Kotsonis, Peter ^c   Hartmann, Elisabeth ^b   Fröhlich, Lothar G ^c   Reif, Andreas ^c   Pfleiderer, Wolfgang ^d   Scheurer, Peter ^e   Ghosh, Dipak K ^f   Schlichting, Ilme ^b,g   Schmidt, Harald H H W ^c,h,i  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF KONSTANZ   (Germany)

^e Vasopharm BIOTECH GmbH   (Germany)

^f DUKE UNIVERSITY   (United States)

^g MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

^h JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIGAND; NEURONAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PTERIDINE DERIVATIVE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BINDING SITE; CONCENSUS PRINICIPAL COMPONENT ANALYSIS; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITOR INTERACTION; ENZYME STRUCTURE; FORCE; GRID FORCE FIELD; LIGAND BASED DRUG DESIGN; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN DOMAIN; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; STRUCTURE BASED DRUG DESIGN; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BIOPTERIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; ISOENZYMES; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN STRUCTURE, TERTIARY; PTERIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22744436091     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050007x     Document Type: Article

References (55)

1. Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357, 593-615.
2. Babu, B. R.; Griffith, O. W. Design of isoform-selective inhibitors of nitric oxide synthase. Curr. Opin. Chem. Biol. 1998, 2, 491-500.
3. Crane, B. R.; Arvai, A. S.; Gachhui, R.; Wu, C.; Ghosh, D. K.; et al. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science 1997, 278, 425-431.
4. Crane, B. R.; Arvai, A. S.; Ghosh, D. K.; Wu, C.; Getzoff, E. D.; et al. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998, 279, 2121-2126.
5. Raman, C. S.; Li, H.; Martasek, P.; Kral, V.; Masters, B. S.; et al. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 1998, 95, 939-950.
6. Fischmann, T. O.; Hruza, A.; Niu, X. D.; Fossetta, J. D.; Lunn, C. A.; et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat. Struct. Biol. 1999, 6, 233-242.
7. Raman, C. S.; Li, H.; Martasek, P.; Babu, B. R.; Griffith, O. W.; et al. Implications for isoform-selective inhibitor design derived from the binding mode of bulky isothioureas to the heme domain of endothelial nitric-oxide synthase. J. Biol. Chem. 2001, 276, 26486-26491.
8. Li, H.; Shimizu, H.; Flinspach, M.; Jamal, J.; Yang, W.; et al. The novel binding mode of N-alkyl-N-hydroxyguanidine to neuronal nitric oxide synthase provides mechanistic insights into NO biosynthesis. Biochemistry 2002, 41, 13868-13875.
9. Fedorov, R.; Hartmann, E.; Ghosh, D. K.; Schlichting, I. Structural basis for the specificity of the nitric-oxide synthase inhibitors W1400 and N(omega)-propyl-L-Arg for the inducible and neuronal isoforms. J. Biol. Chem. 2003,278, 45818-45825.
10. Ji, H.; Li, H.; Flinspach, M.; Poulos, T. L.; Silverman, R. B. Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. J. Med. Chem. 2003, 46, 5700-5711.
11. Flinspach, M. L.; Li, H.; Jamal, J.; Yang, W.; Huang, H.; et al. Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. Nat. Struct. Mol. Biol. 2004, 11, 54-59.
12. Gomez-Vidal, J. A.; Martasek, P.; Roman, L. J.; Silverman, R. B. Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors. J. Med. Chem. 2004, 47, 703-710.
13. Hah, J. M.; Roman, L. J.; Martasek, P.; Silverman, R. B. Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoakyl]-aminopentyl)-N- nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. J. Med. Chem. 2001, 44, 2667-2670.
14. Hah, J. M.; Martasek, P.; Roman, L. J.; Silverman, R. B. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. J. Med. Chem. 2003, 46, 1661-1669.
15. Bommel, H. M.; Reif, A.; Frohlich, L. G.; Frey, A.; Hofmann, H.; et al. Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase. J. Biol. Chem. 1998, 273, 33142-33149.
16. Werner, E. R.; Pitters, E.; Schmidt, K.; Wachter, H.; Werner-Felmayer, G.; et al. Identification of the 4-amino analogue of tetrahydrobiopterin as a dihydropteridine reductase inhibitor and a potent pteridine antagonist of rat neuronal nitric oxide synthase. Biochem. J. 1996, 320, 193-196.
17. Reif, A.; Frohlich, L. G.; Kotsonis, P.; Frey, A.; Bommel, H. M.; et al. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J. Biol. Chem. 1999, 274, 24921-24929.
18. Crane, B. R.; Arvai, A. S.; Ghosh, S.; Getzoff, E. D.; Stuehr, D. J.; et al. Structures of the N-hydroxy-L-arginine complex of inducible nitric oxide synthase oxygenase dimer with active and inactive pterins. Biochemistry 2000, 39, 4608-4621.
19. Kotsonis, P.; Frohlich, L. G.; Raman, C. S.; Li, H.; Berg, M.; et al. Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin. J. Biol. Chem. 2001, 276, 49133-49141.
20. Kotsonis, P.; Frohlich, L. G.; Shutenko, Z. V.; Horejsi, R.; Pfleiderer, W.; et al. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem. J. 2000, 346 (Part 3), 767-776.
21. Brandacher, G.; Zou, Y.; Obrist, P.; Steurer, W.; Werner-Felmayer, G.; et al. The 4-amino analogue of tetrahydrobiopterin efficiently prolongs murine cardiac-allograft survival. J. Heart Lung Transplant 2001, 20, 747-749.
22. Bahrami, S.; Fitzal, F.; Peichl, G.; Gasser, H.; Fuerst, W.; et al. Protection against endotoxemia in rats by a novel tetrahydrobiopterin analogue. Shock 2000, 13, 386-391.
23. Matter, H.; Kotsonis, P.; Klingler, O.; Strobel, H.; Frohlich, L. G.; et al. Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors. J. Med. Chem. 2002, 45, 2923-2941.
24. Kastenholz, M. A.; Pastor, M.; Cruciani, G.; Haaksma, E. E.; Fox, T. GRID/CPCA: a new computational tool to design selective ligands. J. Med. Chem. 2000, 43, 3033-3044.
25. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
26. Boobbyer, D. N.; Goodford, P. J.; McWhinnie, P. M.; Wade, R. C. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J. Med. Chem. 1989, 32, 1083-1094.
27. Wade, R. C.; Clark, K. J.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36, 140-147.
28. Wade, R. C.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J. Med. Chem. 1993, 36, 148-156.
29. GRID, V. Molecular Discovery Ltd.: Oxford, U.K. 2001.
30. Westerhuis, J. A.; Kourti, T.; Macgregor, J. F. Analysis of multiblock and hierarchical PCA and PLS models. J. Chemom. 1998, 12, 301-321.
31. Matter, H.; Defossa, E.; Heinelt, U.; Naumann, T.; Schreuder, H.; et al. Rational Approaches to Drug Design. Proceedings of the 13th European Symposium on Quantitative Structure-Activity Relationships; Prous, Barcelona, 2001; pp 177-185.
32. Ridderstrom, M.; Zamora, I.; Fjellstrom, O.; Andersson, T. B. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem. 2001, 44, 4072-4081.
33. Naumann, T.; Matter, H. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. J. Med. Chem. 2002, 45, 2366-2378.
34. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jorgensen, F. S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/ CPCA approach. J. Med. Chem. 2002, 45, 2675-2684.
35. Pantke, M. M.; Reif, A.; Valtschanoff, J. G.; Shutenko, Z.; Frey, A.; et al. Pterin interactions with distinct reductase activities of NO synthase. Biochem. J. 2001, 356, 43-51.
36. Frohlich, L. G.; Kotsonis, P.; Traub, H.; Taghavi-Moghadam, S.; Al-Masoudi, N.; et al. Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: structure-activity relationship of antagonists of (6R)-5,6,7,8-tetrahydrobiopterin cofactor. J. Med. Chem. 1999, 42, 4108-4121.
37. Yan, X.; Hollis, T.; Svinth, M.; Day, P.; Monzingo, A. F.; et al. Structure-based identification of a ricin inhibitor. J. Mol. Biol. 1997, 266, 1043-1049.
38. Birdsall, D. L.; Finer-Moore, J.; Stroud, R. M. Entropy in bisubstrate enzymes: proposed role of an alternate site in chaperoning substrate into, and products out of, thymidylate synthase. J. Mol. Biol. 1996, 255, 522-535.
39. Blundell, T.; Carney, D.; Gardner, S.; Hayes, F.; Howlin, B.; et al. 18th Sir Hans Krebs lecture. Knowledge-based protein modelling and design. Eur. J. Biochem. 1988, 172, 513-520.
40. Sutcliffe, M. J.; Haneef, I.; Carney, D.; Blundell, T. L. Knowledge based modelling of homologous proteins, Part I: Three-dimensional frameworks derived from the simultaneous superposition of multiple structures. Protein Eng. 1987, 1, 377-384.
41. Sutcliffe, M. J.; Hayes, F. R.; Blundell, T. L. Knowledge based modelling of homologous proteins, Part II: Rules for the conformations of substituted sidechains. Protein Eng. 1987, 1, 385-392.
42. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.
43. Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983, 221, 709-713.
44. Connolly, M. L. Analytical molecular surface calculation. J. Appl. Crystallogr. 1983, 16, 548-558.
45. Heiden, W.; Goetze, T.; Brickmann, J. Fast Generation of Molecular Surfaces from 3D Data Fields with an Enhanced "Marching Cube" Algorithm. J. Comput. Chem. 1993, 14, 246-250.
46. Brickmann, J.; Bertling, H.; Bussian, B. M.; Knoblauch, M.; Waldherr-Teschner, M.; et al. MOLCAD - Interaktive Molekulare Computergrafik auf High-Performance-Computern; GDCh-Fachgruppe Chemie-Information: Würzburg, Tagungsbericht, 1987; pp 93-111.
47. Nakane, M.; Pollock, J. S.; Klinghofer, V.; Basha, F.; Marsden, P. A.; et al. Functional expression of three isoforms of human nitric oxide synthase in baculovirus-infected insect cells. Biochem. Biophys. Res. Commun. 1995, 206, 511-517.
48. Kuin, A.; Aalders, M.; van der Valk, M. A.; Frey, A.; Schmidt, H. H.; et al. Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine. Cancer Chemother. Pharmacol. 1998, 42, 37-45.
49. Ghosh, D. K.; Wu, C.; Fitters, E.; Moloney, M.; Werner, E. R.; et al. Characterization of the inducible nitric oxide synthase oxygenase domain identifies a 49 amino acid segment required for subunit dimerization and tetrahydrobiopterin interaction. Biochemistry 1997, 36, 10609-10619.
50. Ghosh, D. K.; Rashid, M. B.; Crane, B.; Taskar, V.; Mast, M.; et al. Characterization of key residues in the subdomain encoded by exons 8 and 9 of human inducible nitric oxide synthase: a critical role for Asp-280 in substrate binding and subunit interactions. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10392-10397.
51. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26, 795-800.
52. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D: Biol. Crystallogr. 1998, 54, 905-921.
53. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; et al. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc 1984, 106, 765-784.
54. Viale die Casta. 16, GOLPE Multivariate Infometric Analysis; S.T.I.: Perugia, Italy, 1999.
55. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; et al. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.